The role of nonclassical Fc receptor-associated, Ag-B antigens (Ia) in rat allograft enhancement.

PubWeight™: 1.33‹?› | Rank: Top 10%

🔗 View Article (PMC 2190127)

Published in J Exp Med on February 01, 1976

Authors

J P Soulillou, C B Carpenter, A J d'Apice, T B Strom

Articles citing this

Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99

The role of H-2 and Ia antigens in graft-versus-host reactions (GVHR). Presence of host alloantigens on donor cells after GVHR and suppression of GVHR with an anti-Ia antiserum against hose Ia antigens. J Exp Med (1979) 1.17

Emergence of insulin receptors upon alloimmune T cells in the rat. J Clin Invest (1977) 1.09

Role of insulin in the intermediary metabolism of the activated thymic-derived lymphocyte. J Clin Invest (1981) 0.98

Transfer of specific unresponsiveness to organ allografts by thymocytes. Specific unresponsiveness by thymocyte transfer. J Exp Med (1979) 0.90

Association between Ia antigens and the Fc receptors of certain T lymphocytes. J Exp Med (1976) 0.90

The major histocompatibility complex--comparison in the mouse, man, and the rat. A review. Am J Pathol (1978) 0.87

Sharing of Ia antigens between species. I. Detection of Ia specificities shared by rats and mice. J Exp Med (1977) 0.86

The role of subregions of the rat major histocompatibility complex in the rejection and passive enhancement of renal allografts. J Exp Med (1979) 0.81

Role of Ia-like products of the main histocompatibility complex in conditioning skin allograft survival in man. J Clin Invest (1979) 0.79

FcR blocking activity in serum of actively enhanced rat renal allograft recipients due to IgG anti-class II MHC alloantibody. Immunology (1990) 0.79

Use of cryopreserved cells in quality control of human lymphocyte assays: analysis of variation and limits of reproducibility in long-term replicate studies. Clin Exp Immunol (1979) 0.79

The influence of cyclosporin A on alloantibody responses in inbred rats: provisional evidence for a serum factor with antiidiotypic activity. Clin Exp Immunol (1988) 0.77

Immunological properties of subcellular rat lymphocyte preparations. Primary allogeneic stimulation in vitro by fractions containing Ia (RT1-B), but not RT1-A antigens. J Exp Med (1980) 0.75

Failure to block lymphocyte Fc receptor with anti-B lymphocyte sera (anti-DRW) in man. Immunology (1979) 0.75

Articles cited by this

The H-2 major histocompatibility complex and the I immune response region: genetic variation, function, and organization. Adv Immunol (1975) 9.19

The cellular basis of immunological responses. A synthesis of some current views. Lancet (1969) 6.05

Activation of T and B lymphocytes in vitro. III. Presence of Ia determinants on allogeneic effect factor. J Exp Med (1974) 3.29

Evidence for identity or close association of the Fc receptor of B lymphocytes and alloantigens determined by the Ir region of the H-2 complex. J Exp Med (1974) 3.07

Anti-idiotypic antibody in rat transplantation immunity. I. Production of anti-idiotypic antibody in animals repeatedly immunized with alloantigens. J Immunol (1974) 1.59

Renal transplantation in the inbred rat. IX. Hematopoietic origin of an immunogenic stimulus of rejection. Transplantation (1969) 1.49

Studies on the mechanism of immunological enhancement of tumor homografts. I. Specificity of immunological enhancement. J Natl Cancer Inst (1963) 1.32

Interactions of Fc receptors with antibodies against Ia antigens and other cell surface components. J Exp Med (1975) 1.27

Enhancement of renal allografts in rats and man. Transplant Rev (1972) 1.27

Supravital blood studies, using acridine orange fluorescence. Blood (1961) 1.21

What abrogates heart transplant rejection in immunological enhancement? Nature (1974) 1.10

Quantitative semi-micro hemagglutination. A sensitive assay dependent upon cellular dissociation and migration in capillary tubes. J Immunol (1966) 1.07

Ir-associated murine alloantigens: demonstration of multiple Ia specificities in H-2 alloantisera after selective absorptions. J Immunol (1975) 1.01

Immunologic enhancement of renal allografts in the rat. I. Dissociation of graft survival and antibody response. Fed Proc (1971) 0.95

Augmentation of proliferation and in vitro production of cytotoxic cells by 2-ME in the rat. J Immunol (1975) 0.91

Immunologic enhancement of rat renal allografts. I. Comparative morphology of acutely rejecting and passively enhanced grafts. Am J Pathol (1974) 0.91

Humoral and cell-mediated immunity in rats with enhanced kidney allografts. Transplantation (1974) 0.90

Quantitative studies on tumor enhancement in mice. I. Enhancement of sarcoma I induced by IgM, IgG1, and IgG2. J Exp Med (1974) 0.88

Experience with passive enhancement of renal allografts in A (DA x Lewis)F 1 to Lewis Strain combination. Transplantation (1972) 0.87

Modification of the rat alloimmune response by enhancing antibodies and the role of blocking factors in the survival of renal grafts. Transplantation (1975) 0.86

Passive enhancement of mouse skin allografts. Specificity of the antiserum for major histocompatibility. Transplantation (1974) 0.85

Attempted immunological alteration of canine renal allograft donors. Transplantation (1974) 0.83

Immunological enhancement of renal allografts. Transplant Proc (1974) 0.80

Ehancement and hyperacute rejection of skin grafts in the mousefailure to separate cytotoxic and enhancing antibodies from alloantiserum with physicochemical methods. J Immunol (1975) 0.79

Passive enhancement of rat renal allografts with only partial cover of the incompatible Ag-B specificities. Transplantation (1974) 0.79

Articles by these authors

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92

Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 4.05

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet (1998) 3.77

Uncertainty in xenotransplantation: individual benefit versus collective risk. Nat Med (1998) 3.54

Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg (1968) 3.34

Renal transplantation. N Engl J Med (1994) 3.33

B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 3.17

Simultaneous flow cytometric analysis of human T cell activation antigen expression and DNA content. J Exp Med (1983) 2.94

Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med (1999) 2.74

Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68

Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant (2007) 2.61

CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med (1995) 2.48

Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci (1992) 2.47

Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33

IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29

Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol (1984) 2.26

Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med (1994) 2.14

The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12

Cytomegalovirus infection after renal allotransplantation. JAMA (1967) 2.08

Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med (1984) 2.03

Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01

The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J Exp Med (1973) 1.92

SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest (1988) 1.90

Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant (2010) 1.88

Diagnosis of brain death using two-phase spiral CT. AJNR Am J Neuroradiol (1998) 1.86

Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85

Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med (1975) 1.82

Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant (2011) 1.78

Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol (1987) 1.73

Serum complement component levels in human glomerulonephritis. Ann Intern Med (1971) 1.70

Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69

Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med (1983) 1.68

Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant (2007) 1.64

A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol (1985) 1.58

Renal transplantation in the inbred rat. 3. A study of heterologous anti-thymocyte sera. J Exp Med (1967) 1.57

Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation (2000) 1.56

Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant (2010) 1.55

Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. EMBO J (1989) 1.52

T cell death and transplantation tolerance. Immunity (2001) 1.51

Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A (1996) 1.51

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50

The role of antibodies in the rejection and enhancement of organ allografts.?7318. Adv Immunol (1976) 1.48

Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci U S A (1997) 1.48

CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol (1997) 1.47

Factors contributing to the declining mortality rate in renal transplantation. N Engl J Med (1978) 1.45

The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation (1996) 1.45

Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol (2000) 1.45

Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest (1978) 1.44

Alterations in human serum beta-1C-gobulin (C'3) in renal transplantation. Am J Med (1967) 1.42

The IIb-IIIa glycoprotein complex that mediates platelet aggregation is directly implicated in leukocyte adhesion. Cell (1986) 1.40

Intravascular coagulation (IVC) in human renal allograft rejection. Transplant Proc (1969) 1.39

Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant (2013) 1.36

Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma. J Clin Invest (1984) 1.36

Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med (1985) 1.34

Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol (1998) 1.32

Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol (1998) 1.32

Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol (1995) 1.29

Improved B cell typing for HLA-DR using nylon wool column enriched B lymphocyte preparations. Tissue Antigens (1979) 1.29

Early-onset pauciarticular juvenile rheumatoid arthritis associated with human leukocyte antigen-DRw5, iritis, and antinuclear antibody. J Clin Invest (1980) 1.29

Synthetic polypeptide metabolism. 3. Degradation and organ localization of isomeric synthetic polypeptide antigens. J Immunol (1967) 1.28

Two genes required for diabetes in BB rats. Evidence from cyclical intercrosses and backcrosses. J Exp Med (1984) 1.28

Hereditary C2 deficiency: diagnosis and HLA gene complex associations. J Immunol (1976) 1.28

Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol (1992) 1.28

Cyclosporin A spares selectively lymphocytes with donor-specific suppressor characteristics. Transplantation (1981) 1.28

Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transplant (2009) 1.27

Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng (1987) 1.27

Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem (1990) 1.26

Interleukin-2 receptor regulates activation of phosphatidylinositol 3-kinase. J Biol Chem (1991) 1.26

Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol (1996) 1.24

Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med (1988) 1.23

Renal transplantation in the inbred rat. I. Morphologic, immunologic, and functional alterations during acute rejection. Transplantation (1967) 1.22

Role of protein and RNA synthesis in the development of insulin binding sites on activated thymus-derived lymphocytes. J Biol Chem (1979) 1.22

Mapping of the structural gene for the second component of complement with respect to the human major histocompatibility complex. Am J Hum Genet (1979) 1.22

Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol (1994) 1.21

Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci U S A (1986) 1.21

Overcoming memory T-cell responses for induction of delayed tolerance in nonhuman primates. Am J Transplant (2011) 1.20

Accessory cell requirement for activation antigen expression and cell cycle progression by human T lymphocytes. J Immunol (1984) 1.19

SP-40,40 is an inhibitor of C5b-6-initiated haemolysis. Int Immunol (1989) 1.17

A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J Immunol (1987) 1.17

Heritable susceptibility for colitis in mice induced by IL-10 deficiency. Inflamm Bowel Dis (2000) 1.17

Effect of mercaptans and other agents on the human complement component beta-1c-globulin. Immunology (1966) 1.17

IL-2 knockout recipient mice reject islet cell allografts. J Immunol (1995) 1.17

An immunosupressive site of action of heterologous antilymphocyte serum. Lancet (1967) 1.17

Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+-dependent mechanism. J Exp Med (1997) 1.17

Localization of terminal complement components S-protein and SP-40,40 in renal biopsies. Pathology (1989) 1.17

Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int (1998) 1.15

Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation (1998) 1.14

Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation (2000) 1.13

Usefulness of DNA viral load quantification for cytomegalovirus disease monitoring in renal and pancreas/renal transplant recipients. Transplantation (1997) 1.13

A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance. J Clin Invest (1998) 1.13

Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation (1998) 1.13